Adaptimmune Therapeutics plc (NASDAQ:ADAP) COO William C. Bertrand, Jr. Sells 2,234 Shares of Stock


Share on StockTwits

Adaptimmune Therapeutics plc (NASDAQ:ADAP) COO William C. Bertrand, Jr. sold 2,234 shares of the firm’s stock in a transaction on Tuesday, January 12th. The shares were sold at an average price of $6.15, for a total transaction of $13,739.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

William C. Bertrand, Jr. also recently made the following trade(s):

  • On Monday, January 4th, William C. Bertrand, Jr. sold 3,499 shares of Adaptimmune Therapeutics stock. The shares were sold at an average price of $5.33, for a total transaction of $18,649.67.
  • On Monday, December 14th, William C. Bertrand, Jr. bought 207,000 shares of Adaptimmune Therapeutics stock. The stock was acquired at an average cost of $0.69 per share, for a total transaction of $142,830.00.

Shares of ADAP stock opened at $5.82 on Thursday. The firm has a market cap of $757.23 million, a P/E ratio of -5.88 and a beta of 2.40. Adaptimmune Therapeutics plc has a 1-year low of $2.00 and a 1-year high of $13.40. The firm has a fifty day moving average of $5.02 and a two-hundred day moving average of $7.03.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings data on Tuesday, November 10th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.01. The company had revenue of $1.19 million during the quarter, compared to analyst estimates of $1.20 million. Adaptimmune Therapeutics had a negative net margin of 3,858.14% and a negative return on equity of 44.94%. Equities research analysts predict that Adaptimmune Therapeutics plc will post -0.9 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Chicago Partners Investment Group LLC acquired a new position in shares of Adaptimmune Therapeutics in the 3rd quarter valued at about $56,000. Sowell Financial Services LLC boosted its holdings in shares of Adaptimmune Therapeutics by 1,796.8% in the 4th quarter. Sowell Financial Services LLC now owns 11,286 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 10,691 shares during the period. MAI Capital Management acquired a new position in shares of Adaptimmune Therapeutics in the 3rd quarter valued at about $92,000. Wrapmanager Inc. acquired a new position in shares of Adaptimmune Therapeutics in the 3rd quarter valued at about $125,000. Finally, Windsor Creek Advisors LLC acquired a new position in shares of Adaptimmune Therapeutics in the 3rd quarter valued at about $128,000. 99.79% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have recently commented on ADAP shares. SVB Leerink cut their target price on shares of Adaptimmune Therapeutics from $10.00 to $6.00 and set a “market perform” rating on the stock in a research note on Thursday, November 5th. ValuEngine downgraded shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, October 19th. BidaskClub raised shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 25th. Finally, Zacks Investment Research downgraded shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, January 5th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $14.25.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.

Featured Article: What is the Book Value of a Share?

Insider Buying and Selling by Quarter for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.